Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1Carcinoma, Small Cell 1Anus Neoplasms 1

Interventions

Rituximab 6fludarabine phosphate 3Vorinostat 3Specimen Handling 3Biopsy 3sargramostim 2ibrutinib 2binimetinib 2Sunitinib 2RFB4(dsFv)-PE38 recombinant immunotoxin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2MK 2206 2Interferon-alpha 2Ifosfamide 2Flow Cytometry 2Etoposide 2Diphenhydramine 2Cladribine 2Carboplatin 2Bendamustine Hydrochloride 2B3(Fv)-PE38KDEL recombinant immunotoxin 2Analgesia 2Acetaminophen 2venetoclax 1veliparib 1tovorafenib 1tanespimycin 1obatoclax 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Hairy Cell × Epinephrine × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡